

Please try another search
Investing.com - Supernus (NASDAQ: SUPN) reported first quarter EPS of $0.29, $0.02 worse than the analyst estimate of $0.31. Revenue for the quarter came in at $153.76M versus the consensus estimate...
Investing.com - Supernus (NASDAQ: SUPN) reported fourth quarter EPS of $0.43, $0.25 worse than the analyst estimate of $0.68. Revenue for the quarter came in at $167.33M versus the consensus estimate...
Supernus Pharma (SUPN) reported Q4 EPS of $0.43, $0.25 worse than the analyst estimate of $0.68. Revenue for the quarter came in at $167.33 million versus the consensus estimate of $180.38 million.
Supernus Pharmaceuticals, Inc. (Nasdaq: NASDAQ:SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today...
Supernus Pharma (SUPN) reported Q3 EPS of $0.03, $0.32 worse than the analyst estimate of $0.35. Revenue for the quarter came in at $177.35 million versus the consensus estimate of $172.94 million.
Investing.com - Supernus reported on Tuesday third quarter earnings that missed analysts' forecasts and revenue that topped expectations. Supernus announced earnings per share of $0.03 on revenue of...
Supernus Pharma (SUPN) reported Q2 GAAP EPS of $0.14, which may not compare to the analyst estimate of $0.37. Revenue for the quarter came in at $170.1 million versus the consensus estimate of $165.94...
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review